Vaginal bleeding/spotting with conjugated estrogens/bazedoxifene, conjugated estrogens/medroxyprogesterone acetate, and placebo

References

• Barnabei VM, Cochrane BB, Aragaki AK, et al. Menopausal symptoms and treatment-related effects of estrogen and progestin in the women’s health initiative. Obstet Gynecol. 2005;105(5 Pt 1):1063–1073.
   PubMed Web of Science ®Google Scholar
• Arbuckle R, Humphrey L, Abraham L, et al. Qualitative cross-cultural exploration of vaginal bleeding/spotting symptoms and impacts associated with hormone therapy in postmenopausal women to inform the development of new patient-reported measurement tools. Maturitas. 2014;78(3):219–227.
   PubMed Web of Science ®Google Scholar
• Munro MG. Investigation of women with postmenopausal uterine bleeding: clinical practice recommendations. Perm J. 2014;18(1):55–70.
   PubMedGoogle Scholar
• Tarling R, Gale A, Martin-Hirsch P, et al. Experiences of women referred for urgent assessment of postmenopausal bleeding (PMB). J Obstet Gynaecol. 2013;33(2):184–187.
   PubMedGoogle Scholar
• Pickar JH, Boucher M, Morgenstern D. Tissue selective estrogen complex (TSEC): a review. Menopause. 2018. DOI:10.1097/GME.0000000000001095
   Web of Science ®Google Scholar
• Komm BS, Lyttle CR. Developing a SERM: stringent preclinical selection criteria leading to an acceptable candidate (WAY-140424) for clinical evaluation. Ann N Y Acad Sci. 2001;949:317–326.
   PubMed Web of Science ®Google Scholar
• Komm BS, Kharode YP, Bodine PV, et al. Bazedoxifene acetate: a selective estrogen receptor modulator with improved selectivity. Endocrinology. 2005;146(9):3999–4008.
   PubMed Web of Science ®Google Scholar
• Lewis-Wambi JS, Kim H, Curpan R, et al. The selective estrogen receptor modulator bazedoxifene inhibits hormone-independent breast cancer cell growth and down-regulates estrogen receptor alpha and cyclin D1. Mol Pharmacol. 2011;80(4):610–620.
   PubMed Web of Science ®Google Scholar
• Wardell SE, Nelson ER, Chao CA, et al. Bazedoxifene exhibits antiestrogenic activity in animal models of tamoxifen-resistant breast cancer: implications for treatment of advanced disease. Clin Cancer Res. 2013;19(9):2420–2431.
   PubMed Web of Science ®Google Scholar
• Han SJ, Begum K, Foulds CE, et al. The dual ERalpha inhibitory effects of the tissue-selective estrogen complex for endometrial and breast safety. Mol Pharmacol. 2016;89(1):14–26.
   PubMed Web of Science ®Google Scholar
• Ethun KF, Wood CE, Cline JM, et al. Endometrial profile of bazedoxifene acetate alone and in combination with conjugated equine estrogens in a primate model. Menopause. 2013;20(7):777–784.
   PubMed Web of Science ®Google Scholar
• Kharode Y, Bodine PV, Miller CP, et al. The pairing of a selective estrogen receptor modulator, bazedoxifene, with conjugated estrogens as a new paradigm for the treatment of menopausal symptoms and osteoporosis prevention. Endocrinology. 2008;149(12):6084–6091.
   PubMed Web of Science ®Google Scholar
• Lobo RA, Pinkerton JV, Gass ML, et al. Evaluation of bazedoxifene/conjugated estrogens for the treatment of menopausal symptoms and effects on metabolic parameters and overall safety profile. Fertil Steril. 2009;92(3):1025–1038.
   PubMed Web of Science ®Google Scholar
• Pinkerton JV, Utian WH, Constantine GD, et al. Relief of vasomotor symptoms with the tissue-selective estrogen complex containing bazedoxifene/conjugated estrogens: a randomized, controlled trial. Menopause. 2009;16(6):1116–1124.
   PubMed Web of Science ®Google Scholar
• Kagan R, Williams RS, Pan K, et al. A randomized, placebo- and active-controlled trial of bazedoxifene/conjugated estrogens for treatment of moderate to severe vulvar/vaginal atrophy in postmenopausal women. Menopause. 2010;17(2):281–289.
   PubMed Web of Science ®Google Scholar
• Bachmann G, Bobula J, Mirkin S. Effects of bazedoxifene/conjugated estrogens on quality of life in postmenopausal women with symptoms of vulvar/vaginal atrophy. Climacteric. 2010;13(2):132–140.
   PubMed Web of Science ®Google Scholar
• Lindsay R, Gallagher JC, Kagan R, et al. Efficacy of tissue-selective estrogen complex of bazedoxifene/conjugated estrogens for osteoporosis prevention in at-risk postmenopausal women. Fertil Steril. 2009;92(3):1045–1052.
   PubMed Web of Science ®Google Scholar
• Mirkin S, Komm BS, Pan K, et al. Effects of bazedoxifene/conjugated estrogens on endometrial safety and bone in postmenopausal women. Climacteric. 2013;16(3):338–346.
   PubMed Web of Science ®Google Scholar
• Pinkerton JV, Harvey JA, Lindsay R, et al. Effects of bazedoxifene/conjugated estrogens on the endometrium and bone: a randomized trial. J Clin Endocrinol Metab. 2014;99(2):E189–E198.
   PubMed Web of Science ®Google Scholar
• Harvey JA, Pinkerton JV, Baracat EC, et al. Breast density changes in a randomized controlled trial evaluating bazedoxifene/conjugated estrogens. Menopause. 2013;20(2):138–145.
   PubMed Web of Science ®Google Scholar
• Pinkerton JV, Harvey JA, Pan K, et al. Breast effects of bazedoxifene-conjugated estrogens: a randomized controlled trial. Obstet Gynecol. 2013;121(5):959–968.
   PubMed Web of Science ®Google Scholar
• Pickar JH, Yeh IT, Bachmann G, et al. Endometrial effects of a tissue selective estrogen complex containing bazedoxifene/conjugated estrogens as a menopausal therapy. Fertil Steril. 2009;92(3):1018–1024.
   PubMed Web of Science ®Google Scholar
• The North American Menopause Society. The 2017 hormone therapy position statement of The North American Menopause Society. Menopause. 2017;24(7):728–753.
   PubMed Web of Science ®Google Scholar
• Archer DF. Endometrial bleeding in postmenopausal women: with and without hormone therapy. Menopause. 2011;18(4):416–420.
   PubMed Web of Science ®Google Scholar
• Mirkin S, Navarro F, Archer DF. Hormone therapy and endometrial angiogenesis. Climacteric. 2003;6(4):273–277.
   PubMed Web of Science ®Google Scholar
• Lethaby A, Suckling J, Barlow D, et al. Hormone replacement therapy in postmenopausal women: endometrial hyperplasia and irregular bleeding. Cochrane Database Syst Rev. 2004;(3):CD000402
   Google Scholar
• Odmark IS, Jonsson B, Backstrom T. Bleeding patterns in postmenopausal women using continuous combination hormone replacement therapy with conjugated estrogen and medroxyprogesterone acetate or with 17beta-estradiol and norethindrone acetate. Am J Obstet Gynecol. 2001;184(6):1131–1138.
   PubMed Web of Science ®Google Scholar
• Simon JA, Liu JH, Speroff L, et al. Reduced vaginal bleeding in postmenopausal women who receive combined norethindrone acetate and low-dose ethinyl estradiol therapy versus combined conjugated equine estrogens and medroxyprogesterone acetate therapy. Am J Obstet Gynecol. 2003;188(1):92–99.
   PubMed Web of Science ®Google Scholar
• Mattsson LA, Ipsen HE, Granqvist CJ, et al. Ultra-low-dose estradiol and norethisterone acetate: bleeding patterns and other outcomes over 52 weeks of therapy. Climacteric. 2015;18(3):419–425.
   PubMed Web of Science ®Google Scholar
• Rouskova D, Mittmann K, Schumacher U, et al. Effectiveness, tolerability and acceptance of a low-dosed estradiol/dienogest formulation (Lafamme 1 mg/2 mg) for the treatment of menopausal complaints: a non-interventional observational study over 6 cycles of 28 days. Gynecol Endocrinol. 2015;31(7):560–564.
   PubMed Web of Science ®Google Scholar
• Genazzani AR, Schmelter T, Schaefers M, et al. One-year randomized study of the endometrial safety and bleeding pattern of 0.25 mg drospirenone/0.5 mg 17beta-estradiol in postmenopausal women. Climacteric. 2013;16(4):490–498.
   PubMed Web of Science ®Google Scholar
• Archer DF, Dorin M, Lewis V, et al. Effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate on endometrial bleeding. Fertil Steril. 2001;75(6):1080–1087.
   PubMed Web of Science ®Google Scholar